期刊文献+

药物基因组学与临床药师 被引量:8

Pharmacogenomics and Clinical Pharmacists
下载PDF
导出
摘要 药物基因组学是联系基因、药物和疾病间关系的一座桥梁,已逐渐成为临床药师开展临床合理用药实践的有力工具。药物基因组学在临床实践中的应用越来越广泛,通过基因检测对临床合理用药的指导作用尤为突出。通过氯吡格雷和华法林临床用药分析发现,基因分型结果能够为患者提供很好的个体化用药指导。临床药师作为临床治疗团队的成员,可充分利用自身的药学背景优势,结合相关药物基因组学信息,推动临床合理用药。 Pharmacogenomics does not only bring the connection of genes, medicines and diseases, but also become a powerful tool for clinical pharmacists. Pharmacogenomics is commonly used in clinical practice, especially in the implementation of genetic-test results for guiding rational use of medicines. The genotyping results of genes can provide good individualized medication guidance for patients, which can be confirmed by clinical use of the clopidogrel and warfarin. As a member of the clinical treatment team, clinical pharmacists should take advantage of pharmaceutical and pharmacogenomics information to promote rational use of medicines.
作者 刘飞 辛华雯
出处 《医药导报》 CAS 2017年第9期956-961,共6页 Herald of Medicine
基金 国家自然科学基金资助项目(81573506)
关键词 药物基因组学 基因检测 临床药师 Pharmacogenomics Genetic tes t Clinical pharmacists
  • 相关文献

参考文献4

二级参考文献18

  • 1杨剑,缪丽燕.基因多态性对华法林抗凝疗效的影响[J].国际心血管病杂志,2007,34(2):116-118. 被引量:4
  • 2The International Warfarin Pharmacogenetics Consortium. Es- timation of the warfarin dose with clinical and pharmaeogenetic data[J]. N Engl J Med,2009,360(8) :753-764.
  • 3COTTON J M, WORRAL A M, HOBSON A R, et al. In- dividualised assessment of response to clopidogrel in patients presenting with acute coronary syndromes: a role for short thrombelastography? [ J ]. Cardiovasc Ther, 2010, 28(3) :139-146.
  • 4TAUBERTD, VON BECKERATH N, GRIMBERG G, et al. Impact of P-glyeoprotein on elopidogrel absorption[ J ].Clin Pharmaeol Ther, 2006,80 ( 5 ) : 486- 501.
  • 5SIMON T ,VERSTUYFT C ,MARY-KRAUSE M ,et al.Gene- tie determinants of response to elopidogrel and cardiovascular events [ J ], N Engl J Med, 2009,360 (4) : 363-375.
  • 6CHEN L, QIN S, XIE J, et al.Genetie polymorphism analy- sis of CYP2C19 in. Chinese Han populations from different geographic areas of China's Mainland [ J]. Pharmacogenomics, 2008,9 (6) : 691-702.
  • 7ZHOU Q,YU X M, LIU H B,et al.Genetic polymorphism, linkage disequilibrium, haplotypestructure and novel allele analysis of CYP2C19 and CYP2D6 in" Han Chinese [ J ]. Pharmacogenomics, 2009,9(6) : 380-394.
  • 8MEGA J L, CLOSE S L, WIVIOTF S D, et al. Cytochrome P4s0 polymorphisms and response to clopidogrel[ J ]. N Engl J Med, 2009,360 (4) : 354- 362.
  • 9CHANM Y,TAN K,TANH C,et aI. CYP2C19 and PON1 polymorphisms regulating clopidogrelbioactivation in Chinese, Malay and Indian subjects [ J ]. Pharmaco- genomics, 2012,13 ( 5 ) : 533- 542.
  • 10BHATT D L,PARE G, EIKELBOOM J W,et al.The relati- onship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study [ J ]. Eur Heart J, 2012,33 ( 17 ) : 2143-2150.

共引文献87

同被引文献79

引证文献8

二级引证文献30

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部